Publicação
Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis
| dc.contributor.author | Oliveira Santos, Miguel | |
| dc.contributor.author | Carvalho, Mamede | |
| dc.date.accessioned | 2024-05-28T11:27:18Z | |
| dc.date.available | 2024-05-28T11:27:18Z | |
| dc.date.issued | 2024 | |
| dc.description | © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. | pt_PT |
| dc.description.abstract | Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive motor neuron disorder with a fatal outcome 3-5 years after disease onset due to respiratory complications. Superoxide dismutase 1 (SOD1) mutations are found in about 2% of all patients. Tofersen is a novel oligonucleotide antisense drug specifically developed to treat SOD1-ALS patients. Areas covered: Our review covers and discusses tofersen pharmacological properties and its phase I/II and III clinical trials results. Other available drugs and their limitations are also addressed. Expert opinion: VALOR study failed to meet the primary endpoint (change in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale score from baseline to week 28, tofersen arm vs. placebo), but a significant reduction in plasma neurofilament light chain (NfL) levels was observed in tofersen arm (60% vs. 20%). PrefALS study has proposed plasma NfL has a potential biomarker for presymptomatic treatment, since it increases 6-12 months before phenoconversion. There is probably a delay between plasma NfL reduction and the clinical benefit. ATLAS study will allow more insights regarding tofersen clinical efficacy in disease progression rate, survival, and even disease onset delay in presymptomatic SOD1 carriers. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Expert Rev Neurother. 2024 Jun;24(6):549-553 | pt_PT |
| dc.identifier.doi | 10.1080/14737175.2024.2355983 | pt_PT |
| dc.identifier.eissn | 1744-8360 | |
| dc.identifier.issn | 1473-7175 | |
| dc.identifier.uri | http://hdl.handle.net/10451/64903 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Taylor & Francis | pt_PT |
| dc.relation.publisherversion | https://www.tandfonline.com/journals/iern20 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Amyotrophic lateral sclerosis | pt_PT |
| dc.subject | Antisense oligonucleotide | pt_PT |
| dc.subject | Genetics | pt_PT |
| dc.subject | Neurofilament light chain | pt_PT |
| dc.subject | Superoxide dismutase 1 | pt_PT |
| dc.subject | Tofersen | pt_PT |
| dc.title | Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 553 | pt_PT |
| oaire.citation.issue | 6 | pt_PT |
| oaire.citation.startPage | 549 | pt_PT |
| oaire.citation.title | Expert Review of Neurotherapeutics | pt_PT |
| oaire.citation.volume | 24 | pt_PT |
| person.familyName | Oliveira Santos | |
| person.familyName | de Carvalho | |
| person.givenName | Miguel | |
| person.givenName | Mamede | |
| person.identifier.ciencia-id | B511-DD32-12D7 | |
| person.identifier.orcid | 0000-0002-8290-0410 | |
| person.identifier.orcid | 0000-0001-7556-0158 | |
| person.identifier.scopus-author-id | 57217474349 | |
| person.identifier.scopus-author-id | 7101893769 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | eab02009-54a9-4518-8b22-9426433cea69 | |
| relation.isAuthorOfPublication | dd7f55d4-c2b5-4fd2-9bd1-a9542a62f58f | |
| relation.isAuthorOfPublication.latestForDiscovery | eab02009-54a9-4518-8b22-9426433cea69 |